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Abstract
Background: Despite the range of available dura substitutes, limitations such as harvest site morbidity and graft
degradation still exist. As such, there is a need for an optimized dura substitute with superior safety and mechanical
properties than currently available products.
Methods: A retrospective case series was performed to
evaluate the efficacy of a novel, fully synthetic dura substitute. Clinical outcomes (e.g. infectious, reoperation rates,
cerebrospinal fluid leak) and surgeon experiences with the
dura substitute intraoperatively were collected. All methods
were approved by the Institutional Review Board at Washington University School of Medicine.
Conclusion: This study explored the clinical performance
of a fully synthetic nanofabricated dura substitute. Case
analysis demonstrated none required reoperation or had
clinical evidence of CSF leakage, pseudomeningocele, or
meningeal disease after surgery. Results from the physician
survey indicated that this dura substitute offered benefits in
tensile strength appropriate for a variety of neurosurgical
procedures.
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Introduction
Dural substitutes are routinely used in neurosurgical procedures that require disruption of the dura mater to access deeper tissue [1]. A repertoire of materials is available to repair these defects including autograft, xenograft, and recently non-biologic synthetics.
Despite this diversity, limitations exist in using autograft (e.g. poor availability and harvest site morbidity)
or xenograft (e.g. foreign body inflammatory reactions
and graft degradation) [2,3]. Exploration and optimization of the safety and mechanical properties of syn-
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thetic grafts may overcome the shortcomings of other
graft options.
Cerafix® Dura Substitute (Acera Surgical, Inc., St.
Louis, MO) is a unique non-biologic dura substitute
produced via nanofiber electrospinning which provides
impressive strength, handling, and suturability while
mollifying local inflammation [4,5]. This biodegradable
poly (lactic-co-glycolic acid)/polydioxanonematerial is
synthesized into a form that mimics native extracellular matrix to improve tissue in growth, neoduralization,
and watertight closure. In preclinical testing, Cerafix®
demonstrated effective repair of induced dural defects
and successful prevention of cerebrospinal fluid leakage
without infection or damage to underlying cortical tissue
[5]. Compared to DuraMatrix™ (Stryker, Inc., Kalamazoo,
MI), a popular collagen-based dura substitute from bovine dermis or calcaneal tendon, Cerafix® exhibited increased neoduralization, fewer cortical adhesions, and
less inflammation/fibrosis in a rabbit duraplasty model
[5]. Compared to DuraGen Plus™ (Integra LifeSciences,
Inc., Plainsboro, NJ), another commercially available xenogenic dura substitute, Cerafix® demonstrated superior tensile and burst strengths [6].
In this study, we performed a retrospective case series to evaluate the efficacy of a novel, fully synthetic
dura substitute currently in clinical use within neurosurgical operating facilities at Barnes Jewish Hospital/Washington University School of Medicine. The clinical outcomes and surgeon experiences of these cases confirm
that Cerafix® Dura Substitute is a superior option in the
arsenal of available dura substitutes for neurosurgery.

Case Descriptions
Data on three unique individuals who underwent
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Table 1: Surgeon responses regarding the use of Cerafix®
Dura Substitute.
Survey Item

Count

Traditional Product(s)

a

DuraMatrix®

4

DuraGen

3

®

AlloDerm™

3

Bovine pericardium

2

Cerafix Handling vs. Traditional Product(s)
®

a

Easier

5

Same

2

Harder

0

Cerafix Benefits
®

a

smoking history. Physical examination was unremarkable, but brain MRI revealed an enhancing mass in the
right parietal lobe with large surrounding edema extending into right frontal and temporal lobes as well as
along the right internal capsule. There was also approximately 5 mm of leftward midline shift.
He underwent a right frontotemporal craniotomy
with microsurgical resection of the tumor. After resection, the dura was reapproximated with nylon sutures.
A patch of Cerafix® Dura Substitute was sewn in place
followed by an onlay of Cerafix® over the durotomy line
sealed with Tisseel™ fibrin sealant. Postoperative imagingshowed expected postsurgical changes including
resolution of midline shift without hydrocephalus. At
3-month follow up, the patient had no evidence of CSF
leakage, pseudomeningocele, or meningitis.

Non-biologic

5

Tensile strength

4

Fully resorbable

1

Case 2

Non-sided

1

Preparation time

1

A 57-year-old man with dementia presented with
confusion and decreased level of consciousness after a
forward fall and subsequent forehead trauma. Medical
history was significant for pituitary adenoma status post
resection and radiotherapy with secondary adrenal insufficiency, hypothyroidism, and hypogonadism. During
physical examination, he was unable to hold conversation or follow commands. Noncontrast head CT revealed
a 7-mm thick subdural hematoma (SDH) overlying the
right cerebral convexity.

Suitable Procedures/Locations for Cerafix®a
Supratentorial

5

Skull base/Endoscopic

3

Infratentorial/Posterior fossa

3

Spinal

3

Any dural defect

2

Will you use Cerafix for future cases?
®

b

Yes

5

No

0

Could Cerafix® replace your current
product(s)?b
Yes

5

No

0

a
Multiple answers were acceptable for this question; bOnly one
answer was acceptable for this question.

neurosurgery in May 2017 were collected via medical record review. Data points included patient age,
patient sex, preoperative medical history, imaging
findings, primary diagnosis, and postoperative clinical
outcomes i.e. incidence of cerebrospinal fluid (CSF)
leakage, persistent fluid collection, infection, and reoperation within three months of the surgery. Surgeon experiences with the synthetic dura substitute were documented immediately following respective procedures.
Responses were quantified and are reported in Table 1.
All methods were approved by the institutional review
board (IRB) at Washington University School of Medicine.

Case 1
A 63-year-old man with hypertension, hyperlipidemia, and a solitary pulmonary nodule presented with
two to three weeks of declining fine motor skills and
morning headaches. The patient had 1-pack per day
Khandpur et al. Neurosurg Cases Rev 2019, 2:018

Craniotomy for hematoma evacuation was performed.
After copious irrigation, the dura was repaired via interrupted nylon sutures above which a piece of Cerafix® Dura
Substitute was placed and fixed to the bone flap via central tack-up sutures. Postoperative head CT showed interval evolution of the SDH and reduced midline shift with
some effacement of the right lateral ventricle. The patient
expired one month later from respiratory failure and underlying endocrinopathy. No clinical evidence of CSF leakage or infection was noted before then.

Case 3
A 66-year-old man with history of a fourth ventricle
ependymoma status post-resection and chemoradiotherapy presented with weeks of worsening diplopia,
episodic confusion, and overall visual decline. Physical
examination revealed inducible diplopia on extreme lateral gaze bilaterally. Preoperative imaging demonstrated a trilobed peripherally enhancing irregular mass in
the left temporooccipital region with central necrosis
and associated diffusion restriction. Extension to the
splenium was also noted.
The patient underwent craniotomy and microsurgical resection of the left occipital mass later determined
to be glioblastoma multiforme. Dura defects were
closed using Vicryl® (Ethicon, Inc., Bridgewater, NJ) sutures and an onlay of Cerafix® Dura Substitute. Postoperative MRI showed T1 hyperintensity in the resection
• Page 2 of 3 •
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cavity consistent with residual blood products. There
was patchy enhancement in the splenium suspicious for
residual tumor. At 3-month follow up, the patient had
completed chemotherapy and craniospinal radiation.
Symptomatically, he had returned to neurological baseline although brain MRI continued to show marginal enhancement of the resection cavity concerning for tumor
progression. He had no persistent fluid collections, CSF
leaks, or clinical signs of infection over this period.

Conclusions
In their review of available dural grafting materials,
Berjano, et al. proposed characteristics of the ideal dura
substitute: watertight closure, low antigenicity/tissue
toxicity, free from potential risk of infection, easy handling, and availability [7]. Although options for substitutes exist, they are mostly limited to autogenic and xenogenic materials with poor availability, risk of disease
transmission, or higher antigenicity.
Autografts are obtained from pericranial tissue or
tendinous fascia lata. Although they do not elicit significant inflammation, their use is limited by host site
morbidity and larger dural defect areas [5]. Allografts
from cadaveric dura are more available but portend
serious risk of infection [8,9]. Xenografts from native
bovine or porcine tissues offer a similar feel to human
dura as well as robust cellular infiltration and angiogenesis [3,5]. However, graft degradation is known to occur
prematurely resulting in weak tissue over the dural defect [3,5]. The tradeoff between mechanical propertiesand resorption ability in addition to the risk of zoonosis
and allergic reactions restricts their routine application
[3,10]. Effectiveness of other synthetic grafts (e.g. Preclude™ and Ethisorb™ dura substitutes) is limited to
preclinical testing where they often do not uphold similar mechanical properties [11].
This study explored the clinical performance of a fully synthetic nanofabricated dura substitute to optimize
critical dura substitute properties. Analysis of patient
outcomes showed that none required reoperation or
had clinical evidence of CSF leakage, pseudomeningocele, or meningeal pathology. The median length of hospital stay after surgery was 4 days. While this dura substitute was examined in the adult population, its utility
could be expanded to include pediatric cases as well.
Further studies are required. Results from the physician
survey indicated that Cerafix® was mostly easier to use,
offered benefits in tensile strength, and appropriate for
a range of surgical procedures/locations (Table 1) [12].
These clinical observations and surgeon experiences
support the use of Cerafix® Dura Substitute in the neurosurgical arena.
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